



WARRANTS OF SERIES TO 5 **PROSTATYPE GENOMICS AB**

EXERCISE PERIOD: 3-17 SEPTEMBER 2025

IMPORTANT INFORMATION

This information document has been prepared by Prostatype Genomics AB ("Prostatype Genomics" or the "Company"). Readers are asked to check out the prospectus that Prostatype Genomics AB put out on May 16, 2025, when the Company conducted a rights issue of units, for a description of the risks that come with investing in the Company. You can download the prospectus from the Company's website (www.prostatypegenomics.com).

FREDRIK RICKMAN, CEO, COMMENTS

Prostate cancer is the most common form of cancer among men in Europe and the second most common worldwide. Despite of this, it remains one of the most challenging cancer diagnoses when it comes to making the right treatment decisions. Many patients receive overly aggressive treatment – with serious side effects that affect their quality of life – while others are undertreated and risk their disease worsening. This is where Prostatype Genomics makes a real difference.

Our company is based on more than fifteen years of groundbreaking research at Karolinska Institutet, with a clear ambition: to provide doctors with better tools for making individualized and more accurate treatment decisions for prostate cancer. The result is Prostatype® – a patented and IVDR-approved genetic test that combines advanced molecular biology with AI-based analysis. By utilizing existing biopsy material from the time of diagnosis, the test adds a whole new layer of information – without the patient having to undergo further procedures. It is a clear example of how precision medicine can improve both healthcare outcomes and quality of life.



Over the past two years, we have built a focused commercialization strategy in which we conduct local validation studies in parallel with sales activities to establish clinical acceptance. Today, Prostatype® is commercially available in selected markets in EMEA – including the Nordic countries, Spain, and Italy – and is undergoing validation in Taiwan. However, it is the US, the world's largest market for prognostic genetic testing, where Prostatype® was launched commercially in 2024, that is our strategic main focus. There, we are awaiting news of Medicare approval, a milestone that could enable broad reimbursement and accelerate our commercial impact in US healthcare.

With the product fully developed, a proven business model with strong margins, and growing interest from the market, we are facing a decisive stage. Through the exercise of options, we intend to secure financing for parts of our continued expansion and completion of the Medicare process.

We are convinced that Prostatype® has the potential to become a new standard in prostate cancer diagnostics – with significant implications for patients, healthcare providers and society at large. We also see clear opportunities to create long-term value for our shareholders, and we look to the future with great confidence.

Fredrik Rickman – CEO Prostatype Genomics AB

INVESTMENT HIGHLIGHTS



Patented and IVDR-approved gene technology for prostate cancer – Prostatype® is a prognostic genetic test for confirmed prostate cancer based on gene expression in primary embryonic cancer stem cells – a test that contributes to improved treatment decisions and thus reduces the risk of over- and under-treatment.



Strong clinical potential with global interest – Prostatype® addresses a widespread global need for better decision support in prostate cancer treatment and is used as a complement to existing clinical tools – creating potential for a broad impact in healthcare.



Clear commercial focus and geographical expansion – The Company has initiated commercialization in Sweden, Spain, Italy, and Taiwan, with a particular focus on the US, where the Medicare approval process is at an advanced stage – a key factor for broad market penetration.



Solid business model with attractive margins and low development risk – The product is fully developed, market-ready, and launched in both the US and Europe, and the Company is now focusing on building sales and demonstrating recurring revenue rather than product development – which reduces operational risk.



Breakthrough in the US market is expected in the near future – The ongoing application for Medicare approval in the US opens up for reimbursement and establishment in the world's largest market for prostate cancer – a breakthrough announcement is expected in 2025. The Company has already started invoicing private American insurance companies.

INTRODUCTION TO PROSTATYPE GENOMICS

Prostatype Genomics is the result of over fifteen years of research into prostate cancer genomics. The Company was founded in 2007 as a spin-off from the Karolinska Cancer Center (Karolinska Institutet, Stockholm). This led to the development of the Prostatype® Test System, which is now IVDR-approved and on the market. In addition to Europe, Prostatype® has also been launched in the US and is in clinical use. All regulatory and commercial requirements have therefore already been met for the US market as well.

Prostatype® is a patented genetic test for the prognosis of prostate cancer that has been developed to provide the complementary information often required to select the optimal treatment strategy for each unique patient. The Prostatype® system identifies the genetic fingerprint of prostate cancer by measuring gene expression, focusing on the genes of embryonic cancer stem cells in the tissue sample (biopsy) already obtained when the patient was diagnosed. In other words, Prostatype Genomics uses the patient's original biopsy, which means that the patient in question does not need to undergo additional tests to diagnose prostate cancer, while increasing the accuracy of the treatment decision.

Prostatype® is intended to be used as a complement to the current clinical diagnostic and prognostic methods routinely used in healthcare. Prostatype® is patented and, in the opinion of the Board, is the only genetic test for prostate cancer that focuses on measuring gene expression with a focus on embryonic cancer stem cells in prostate cancer in a format that allows independent hospitals to perform tests.

The test analyzes gene expression in cancer cells from prostate tissue and, in combination with advanced algorithms and data analysis, provides decision support for optimal treatment of individual patients when prostate cancer has been confirmed. Using AI (artificial intelligence) technology, the Prostatype Genomics genetic test makes it possible to better predict prostate cancer and categorize the patient's condition into different risk types. In this way, the test can reduce the risk of over- or under-treatment, which in many cases leads to significant discomfort for the patient in the form of life-long side effects such as impotence and incontinence.

The Prostatype Genomics Test System is a package consisting of the Prostatype® RTqPCR kit, patient databases and algorithms, PWS (Prostatype Web System) and the associated P-score.

STRATEGY

Prostatype Genomics has begun commercializing Prostatype® and is pursuing a focused strategy to maximize its impact in selected markets in the most cost-effective manner, with the aim of achieving recurring sales revenue and proving the business model in different geographical markets. In addition to focused sales efforts, it is important to simultaneously strengthen the scientific foundation through local validation studies, which is often a prerequisite for doctors and healthcare providers to adopt a new product. The US is the Company's strategic main focus, and operations are also conducted in selected EMEA markets in the Nordic region, with a focus on Sweden, Spain, Italy, and Taiwan.

Over the past two years, the Company has systematically worked to map and evaluate different markets and approaches from a commercial perspective in various countries in order to identify whether the following criteria are met or can be met in the near future:

- Clinical acceptance for genetic testing in prostate cancer and confirmed clinical use, and
- Market acceptance through clinics evaluating and starting to use Prostatype®

THE OFFER IN BRIEF

Exercise period: 3-17 September 2025.

Exercise price: SEK 0.52 per share.

Issue volume: upon full exercise of warrants of series TO5, the Company will receive approximately SEK 11.8 million before transaction costs.

Last day of trading in TO5: 15 September 2025.

Please note that your bank or custodian may, for administrative reasons, adopt a final date of use that is earlier than 17 September, 2025. For questions regarding your specific deadline, please contact your bank/custodian.

SUMMARY OF TERMS AND CONDITIONS FOR TO5

SUMMARY OF TERMS FOR TO5

There are 22,623,789 outstanding warrants of series TO5. Holders of warrants of series TO5 have the right to, for each (1) warrant, subscribe for one (1) new share in Prostatype Genomics AB to a price of SEK 0.52 per share.

Subscription with support of warrants of series TO5 takes place from and including 3 September 2025 to and including 17 September 2025. Subscription shall be made by simultaneous cash payment no later than 17:00 CET on 17 September 2025.

YOU NEED TO RESPOND TO THE OFFER AS A WARRANT HOLDER – HERE'S HOW TO EXERCISE YOUR TO5 WARRANTS

In order for your warrants not to expire worthless, you must subscribe for new shares, supported by warrants, no later than 5:00 p.m. CET on 17 September 2025, or sell your warrants no later than 15 September 2025. The ISIN code for TO5 is SE0024990063.

You can have your warrants registered in two ways:

1. In a securities account at a bank or other custodian (such as Avanza or Nordnet), in an investment savings account (ISK), or in an endowment insurance policy (KF). Your warrants are then registered with the custodian.
2. In a VP account (a VP account begins with three zeros and has a total of 12 digits). Your warrants are then directly registered.

Subscription and payment for new shares, based on warrants, shall be made to the respective bank or other custodian where the warrants are registered. Subscription and payment shall be made in accordance with the instructions provided by each such bank or custodian. Usually, the bank/custodian will send a digital notice to the account holder; otherwise, it is usually sufficient to log in to the securities account from the first day of the exercise period in order to obtain instructions on how to exercise warrants to subscribe for new shares. Please contact your bank or custodian if you cannot find these instructions.

Please note that banks and other administrators may set different time limits for subscription, so it is recommended that you contact your bank/administrator early during the exercise period to obtain information about subscription and payment. Subscribed and paid shares may be registered in your securities account as "interim shares" or "IA" until the registration of the issue has been completed with the Swedish Companies Registration Office, at which point the interim shares will automatically be converted into ordinary shares in Prostatype Genomics AB.

TO5 THAT ARE DIRECT REGISTERED

No issue statement will be sent out. Subscription for new shares, based on warrants, shall be made by submitting a fully completed subscription form to Nordic Issuing AB via email. When submitting the subscription form to Nordic Issuing AB, payment shall be made in accordance with the payment instructions on the subscription form. The subscription form and this information sheet are available on the Company's website (www.prostatypegenomics.com) and Nordic Issuing AB's website (www.nordic-issuing.se).

The subscription application form and payment must be received by Nordic Issuing AB no later than 5:00 p.m. CET on 17 September 2025. Subscribed and paid shares will be registered in your VP account as "interim shares" or "IA" until the registration of the issue has been completed with the Swedish Companies Registration Office, at which point the interim shares will automatically be converted into ordinary shares in Prostatype Genomics AB.

SUBSCRIPTION OVER EUR 15,000 IF APPLICABLE

If your subscription amounts to or exceeds EUR 15,000, a money laundering form must be completed and submitted to Nordic Issuing AB in accordance with the Swedish Money Laundering and Terrorist Financing Prevention Act (2017:630) at the same time as payment is made. Please note that interim shares cannot be booked out, even if payment has been received, until the money laundering check has been received by Nordic Issuing AB. Money laundering forms are available from Nordic Issuing AB.

IMPORTANT DATES FOR WARRANTS OF SERIES TO5

- 3 September 2025 – exercise period starts
- 15 September 2025 – last day of trading in warrants
- 17 September 2025 – exercise period ends
- 18 September 2025 – planned date of announcement of outcome of warrant exercise
- Around 30 September 2025 – planned date for change from interim shares to shares

PLEASE NOTE – in order for your warrants not to expire worthless, you must actively subscribe and pay for shares no later than 5 p.m. CEST on 17 September 2025, or sell your warrants no later than 15 September 2025. If you have any questions regarding warrants of series TO5, please contact Navia Corporate Finance AB, Gemstone Capital ApS, or Nordic Issuing AB.

Navia Corporate Finance AB and Gemstone Capital ApS are acting as financial advisors to Prostatype Genomics in connection with the warrant exercise. Nordic Issuing AB is acting as the issuing agent and Advokatfirman Lindahl is acting as legal advisor.

For complete information about the offer, please refer to the prospectus published by the Company on May 16, 2025.

Navia Corporate Finance AB
E-mail: info@naviacf.se

Gemstone Capital ApS
E-mail: info@gemstonecapital.com

Nordic Issuing AB
E-mail: info@nordic-issuing.se